229 related articles for article (PubMed ID: 31826983)
1. Distinct neural mechanisms for the prosocial and rewarding properties of MDMA.
Heifets BD; Salgado JS; Taylor MD; Hoerbelt P; Cardozo Pinto DF; Steinberg EE; Walsh JJ; Sze JY; Malenka RC
Sci Transl Med; 2019 Dec; 11(522):. PubMed ID: 31826983
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA).
Young MB; Norrholm SD; Khoury LM; Jovanovic T; Rauch SAM; Reiff CM; Dunlop BW; Rothbaum BO; Howell LL
Psychopharmacology (Berl); 2017 Oct; 234(19):2883-2895. PubMed ID: 28741031
[TBL] [Abstract][Full Text] [Related]
3. Long-term compulsive exercise reduces the rewarding efficacy of 3,4-methylenedioxymethamphetamine.
Chen HI; Kuo YM; Liao CH; Jen CJ; Huang AM; Cherng CG; Su SW; Yu L
Behav Brain Res; 2008 Feb; 187(1):185-9. PubMed ID: 17949827
[TBL] [Abstract][Full Text] [Related]
4. MDMA enhances empathy-like behaviors in mice via 5-HT release in the nucleus accumbens.
Rein B; Raymond K; Boustani C; Tuy S; Zhang J; St Laurent R; Pomrenze MB; Boroon P; Heifets B; Smith M; Malenka RC
Sci Adv; 2024 Apr; 10(17):eadl6554. PubMed ID: 38657057
[TBL] [Abstract][Full Text] [Related]
5. Activation of protein kinase C (PKC) by 3,4-methylenedioxymethamphetamine (MDMA) occurs through the stimulation of serotonin receptors and transporter.
Kramer HK; Poblete JC; Azmitia EC
Neuropsychopharmacology; 1997 Sep; 17(3):117-29. PubMed ID: 9272479
[TBL] [Abstract][Full Text] [Related]
6. Separating the agony from ecstasy: R(-)-3,4-methylenedioxymethamphetamine has prosocial and therapeutic-like effects without signs of neurotoxicity in mice.
Curry DW; Young MB; Tran AN; Daoud GE; Howell LL
Neuropharmacology; 2018 Jan; 128():196-206. PubMed ID: 28993129
[TBL] [Abstract][Full Text] [Related]
7. Intracranial self-administration of MDMA into the ventral striatum of the rat: differential roles of the nucleus accumbens shell, core, and olfactory tubercle.
Shin R; Qin M; Liu ZH; Ikemoto S
Psychopharmacology (Berl); 2008 Jun; 198(2):261-70. PubMed ID: 18389222
[TBL] [Abstract][Full Text] [Related]
8. Serotonergic modulation of 3,4-methylenedioxymethamphetamine (MDMA)-elicited reduction of response rate but not rewarding threshold in accumbal self-stimulation.
Lin HQ; Jackson DM; Atrens DM; Christie MJ; McGregor IS
Brain Res; 1997 Jan; 744(2):351-7. PubMed ID: 9027397
[TBL] [Abstract][Full Text] [Related]
9. Serotonergic-dopaminergic mediation of MDMA's discriminative stimulus effects in a three-choice discrimination.
Goodwin AK; Pynnonen DM; Baker LE
Pharmacol Biochem Behav; 2003 Mar; 74(4):987-95. PubMed ID: 12667914
[TBL] [Abstract][Full Text] [Related]
10. The rewarding properties of MDMA are preserved in mice lacking mu-opioid receptors.
Robledo P; Mendizabal V; Ortuño J; de la Torre R; Kieffer BL; Maldonado R
Eur J Neurosci; 2004 Aug; 20(3):853-8. PubMed ID: 15255997
[TBL] [Abstract][Full Text] [Related]
11. Methylenedioxymethamphetamine-induced inhibition of neuronal firing in the nucleus accumbens is mediated by both serotonin and dopamine.
Obradovic T; Imel KM; White SR
Neuroscience; 1996 Sep; 74(2):469-81. PubMed ID: 8865198
[TBL] [Abstract][Full Text] [Related]
12. Reinforcing effects of certain serotonin-releasing amphetamine derivatives.
Marona-Lewicka D; Rhee GS; Sprague JE; Nichols DE
Pharmacol Biochem Behav; 1996 Jan; 53(1):99-105. PubMed ID: 8848466
[TBL] [Abstract][Full Text] [Related]
13. Methylenedioxymethamphetamine depresses glutamate-evoked neuronal firing and increases extracellular levels of dopamine and serotonin in the nucleus accumbens in vivo.
White SR; Duffy P; Kalivas PW
Neuroscience; 1994 Sep; 62(1):41-50. PubMed ID: 7816211
[TBL] [Abstract][Full Text] [Related]
14. Examining the role of oxytocin in the interoceptive effects of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') using a drug discrimination paradigm in the rat.
Broadbear JH; Tunstall B; Beringer K
Addict Biol; 2011 Apr; 16(2):202-14. PubMed ID: 21070509
[TBL] [Abstract][Full Text] [Related]
15. Role of 5-HT
Esaki H; Sasaki Y; Nishitani N; Kamada H; Mukai S; Ohshima Y; Nakada S; Ni X; Deyama S; Kaneda K
Eur J Pharmacol; 2023 May; 946():175653. PubMed ID: 36907260
[TBL] [Abstract][Full Text] [Related]
16. Contribution of analog signaling to neurotransmitter interactions and behavior: Role of transporter-mediated nonquantal dopamine release.
Román V; Kedves R; Kelemen K; Némethy Z; Sperlágh B; Lendvai B; Vizi ES
Physiol Rep; 2021 Nov; 9(21):e15088. PubMed ID: 34762352
[TBL] [Abstract][Full Text] [Related]
17. MDMA-induced c-Fos expression in oxytocin-containing neurons is blocked by pretreatment with the 5-HT-1A receptor antagonist WAY 100635.
Hunt GE; McGregor IS; Cornish JL; Callaghan PD
Brain Res Bull; 2011 Aug; 86(1-2):65-73. PubMed ID: 21745546
[TBL] [Abstract][Full Text] [Related]
18. MDMA induced dopamine release in vivo: role of endogenous serotonin.
Koch S; Galloway MP
J Neural Transm (Vienna); 1997; 104(2-3):135-46. PubMed ID: 9203077
[TBL] [Abstract][Full Text] [Related]
19. Repeated exposure to methylenedioxymethamphetamine (MDMA) alters nucleus accumbens neuronal responses to dopamine and serotonin.
Obradovic T; Imel KM; White SR
Brain Res; 1998 Feb; 785(1):1-9. PubMed ID: 9526029
[TBL] [Abstract][Full Text] [Related]
20. Repeated intermittent MDMA binges reduce DAT density in mice and SERT density in rats in reward regions of the adolescent brain.
Kindlundh-Högberg AM; Schiöth HB; Svenningsson P
Neurotoxicology; 2007 Nov; 28(6):1158-69. PubMed ID: 17692920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
